BioCentury
ARTICLE | Clinical News

CHF 6001: Phase I data

October 29, 2012 7:00 AM UTC

A double-blind, placebo-controlled, U.K. Phase I trial in about 74 healthy volunteers showed that single and repeated ascending-doses of up to 2,000 µg inhaled CHF 6001 for 7 days were well tolerated,...